Tscan Therapeutics Inc

+0.05 (+1.64%)
Other Pre-Announcement

TScan Therapeutics Reports Q2 Loss Per Share Of $7.69

Published: 08/19/2021 11:36 GMT
Tscan Therapeutics Inc (TCRX) - Tscan Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress.
Q2 Loss per Share $7.69.
Ind Submissions Expected in Q4 2021 for Lead Liquid Tumor Tcr-t Therapy Candidates, Tsc-100 and Tsc-101.
Tscan Therapeutics - As of June 30, 2021, Had Cash, Equivalents Totaling $106.2 Million, Which Excludes Gross Proceeds of $100 Million From Ipo.